Fayyaz Mujtaba is leaving Wellington Management, the sole subadvisor of Hartford Healthcare, and will no longer serve as a manager of this strategy, effective immediately. His departure does not affect the strategy’s Above Average People rating or its Morningstar Medalist Rating of Silver or Bronze, depending on share class.
Hartford Healthcare I HGHIX
- NAV / 1-Day Return 42.08 / +1.11 %
- Total Assets 1.1 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.010%
- Distribution Fee Level Above Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,000
- Status Open
- TTM Yield —
- Turnover 32%
USD | NAV as of Jun 01, 2024 | 1-Day Return as of Jun 01, 2024, 12:15 AM GMT+0
Morningstar’s Analysis HGHIX
Will HGHIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 44.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 11.98 | 127.7 Mil | Healthcare |
UnitedHealth Group Inc | 6.82 | 72.7 Mil | Healthcare |
Merck & Co Inc | 6.62 | 70.6 Mil | Healthcare |
Danaher Corp | 3.90 | 41.6 Mil | Healthcare |
Boston Scientific Corp | 3.12 | 33.3 Mil | Healthcare |
Stryker Corp | 2.80 | 29.9 Mil | Healthcare |
Thermo Fisher Scientific Inc | 2.58 | 27.5 Mil | Healthcare |
HCA Healthcare Inc | 2.43 | 25.9 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.29 | 24.5 Mil | Healthcare |
AbbVie Inc | 2.27 | 24.2 Mil | Healthcare |